Antiviral agents for dengue virus
Dengue virus (DENV) is a mosquito-borne pathogen responsible for a spectrum of illnesses, including dengue fever, dengue hemorrhagic fever, and dengue shock syndrome. Nearly half of the global population is at risk of DENV infection, making it a pressing public health issue worldwide. The limited cross-protection among the four DENV serotypes (DENV1-4) and the phenomenon of antibody-dependent enhancement (ADE) have posed significant challenges to the development of effective dengue vaccines. Furthermore, there are currently no specific antiviral treatments available. This review provides an overview of DENV's key characteristics, clinical manifestations, and recent advancements in antiviral drug development- including the repurposing of approved drugs, peptide-based antiviral agents, therapeutic antibodies, natural products with antiviral potential, and host factor inhibitors- aiming to offer critical insights to inform strategies for managing and preventing dengue outbreaks.
Authors
- Yigang Xu (ORCID: https://orcid.org/0000-0001-7085-7227)
- Minghui Yang (ORCID: https://orcid.org/0000-0002-7612-8137)
- Chenguang Shen (ORCID: https://orcid.org/0000-0001-8607-3750)
- Yang Yang (ORCID: https://orcid.org/0000-0003-0428-5480)
- Yuxin Tian (ORCID: https://orcid.org/0009-0001-5434-0946)
- Mengyuan Zhao (ORCID: https://orcid.org/0000-0003-4662-2975)
- Yinghan Jiang
- Yanran Wang (ORCID: https://orcid.org/0000-0002-2989-7398)
Institutions
- Beijing Institute of Technology (CN)
- Southern University of Science and Technology (CN)
- Beijing Research Institute of Mechanical and Electrical Technology (CN)
- Zhujiang Hospital (CN)
- Beijing Children’s Hospital (CN)
- Zhuhai Institute of Advanced Technology (CN)
- Southern Medical University (CN)
Publication Details
- Journal
- Virologica Sinica
- Published
- 2025-11-26
- DOI
- https://doi.org/10.1016/j.virs.2025.11.009
- Primary Topic
- Mosquito-borne diseases and control
- Type
- article
- Field-Weighted Citation Impact
- 0.00